Baseline, Early Changes, and Residual Albuminuria
Dominique van Mil(University Medical Center Groningen), Hiddo J.L. Heerspink(University Medical Center Groningen), Anna Maria Langkilde(AstraZeneca (Sweden)), Glenn M. Chertow(Stanford Health Care), C. David Sjöström(University Medical Center Groningen), Priya Vart(University Medical Center Groningen), David C. Wheeler(University College London), Peter Rossing(Steno Diabetes Centers), Ron T. Gansevoort(University Medical Center Groningen), R Correa-Rotter(University of Utah), Robert D. Toto(Southwestern Medical Center)
Cited by 10
Related Papers
Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization
|New England Journal of Medicine|2004|11.4k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
|New England Journal of Medicine|2007|4.6k
Acute Kidney Injury, Mortality, Length of Stay, and Costs in Hospitalized Patients
|Journal of the American Society of Nephrology|2005|3.4k